$65.71
0.560.86%
At close: -
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Comments
Loading...
Sector
Healthcare
Region
US
AUM
678.45M
Fund Score
iShares U.S. Pharmaceutical ETF (ARCA:IHE) Quotes, Forecast and News Summary
iShares U.S. Pharmaceutical ETF (ARCA: IHE) stock price, news, charts, stock research, profile.
| Open | $65.88 |
| High | $66.47 |
| 52 Wk High | $72.94 |
| AUM | 678.45M |
| Dividend | $1.88 |
| Ex-Div Date | Jun 11, 2024 |
| Volume | 53.19K |
| Market Cap | $229.77B |
| Mgmt Fee | 0.39% |
| P/E Ratio | 19.62 |
| Prev. Close | $65.15 |
| Low | $65.58 |
| 52 Wk Low | $59.82 |
| Shares Out | 10.15M |
| Yield | 2.70% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 63.21K |
| Beta | 0.66 |
| Avg. Expense Ratio | 0.39% |
| P/B Ratio | 3.07 |
Recent News
FAQ
Q
How do I buy iShares U.S. Pharmaceutical ETF (IHE) stock?
A
You can purchase shares of iShares U.S. Pharmaceutical ETF (ARCA:IHE) through any online brokerage.
Q
Who are iShares U.S. Pharmaceutical ETF (IHE) competitors?
A
There are no as such competitors for iShares U.S. Pharmaceutical ETF.
Q
What is the forecast, or price target, for iShares U.S. Pharmaceutical ETF (IHE) stock?
A
There is no analysis for iShares U.S. Pharmaceutical ETF to provide a consensus price target.
Q
What is the current price for iShares U.S. Pharmaceutical ETF (IHE)?
A
The stock price for iShares U.S. Pharmaceutical ETF (ARCA: IHE) is $65.71 last updated December 20, 2024 at 8:00 PM EST.
Q
Does iShares U.S. Pharmaceutical ETF (IHE) pay a dividend?
A
A quarterly cash dividend of 0.35 per share of Class A Common Stock. The quarterly cash dividend was payable on December 21, 2018 to stockholders of record on December 17, 2018.
Q
When is iShares U.S. Pharmaceutical ETF (ARCA:IHE) reporting earnings?
A
iShares U.S. Pharmaceutical ETF does not have any upcoming earnings scheduled.
Q
Is iShares U.S. Pharmaceutical ETF (IHE) going to split?
A
There is no upcoming split for iShares U.S. Pharmaceutical ETF.
| Open | $65.88 |
| High | $66.47 |
| 52 Wk High | $72.94 |
| AUM | 678.45M |
| Dividend | $1.88 |
| Ex-Div Date | Jun 11, 2024 |
| Volume | 53.19K |
| Market Cap | $229.77B |
| Mgmt Fee | 0.39% |
| P/E Ratio | 19.62 |
| Prev. Close | $65.15 |
| Low | $65.58 |
| 52 Wk Low | $59.82 |
| Shares Out | 10.15M |
| Yield | 2.70% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 63.21K |
| Beta | 0.66 |
| Avg. Expense Ratio | 0.39% |
| P/B Ratio | 3.07 |
ETF Details
| Sector | Healthcare |
| Category | High Performer-High Growth |
| Investment Style | Large Cap Blend |
| Fund Inception | May 1, 2006 |
| Managers | Paul Whitehead Jennifer Hsui Greg Savage Amy Whitelaw |
| Definition | A Equity Fund portfolio full of stocks with both strong financial performance and superior growth potential |
Investment Policy
The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Popular Channels
Tools & Features
Partners & Contributors
About Benzinga
© 2024 Benzinga | All Rights Reserved